Hasil Pencarian - Pablo Maroto

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting

    Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting oleh Javier Puente, Enrique Grande, Ana Medina, Pablo Maroto, Nuria Lainez, Jose Angel Arranz

    Diterbitkan 2017-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment

    Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment oleh Elisabet Cantó, Georgia Anguera, Natalia Jiménez, Begoña Mellado, Ona Ramírez, Anais Mariscal, Pablo Maroto, Silvia Vidal

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Cabozantinib for the treatment of solid tumors: a systematic review

    Cabozantinib for the treatment of solid tumors: a systematic review oleh Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Daniel Castellano

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

    Cabozantinib combination therapy for the treatment of solid tumors: a systematic review oleh Daniel Castellano, Andrea B. Apolo, Camillo Porta, Jaume Capdevila, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Pablo Maroto

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy

    Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy oleh Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora, Maria Mulet, Maria Soledad Garcia-Cuerva, Ana Palomino, Georgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group

    Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group oleh Antonio Gómez Caamaño, Ana M. García Vicente, Pablo Maroto, Alfredo Rodríguez Antolín, Julián Sanz, María Almudena Vera González, Miguel Ángel Climent, on behalf of the Spanish Oncology Genitourinary (SOGUG) Multisiciplinary Working Group

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

    Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE oleh Javier Puente, Urbano Anido, Miguel Ángel Climent, Enrique Gonzalez-Billalabeitia, Nuria Lainez, Julio Lambea, José Pablo Maroto, Maria Jose Mendez-Vidal, Álvaro Montesa, Angel Rodriguez, Curro Zambrana, Aránzazu González-del-Alba

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study

    Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study oleh Magnus Lindskog, Anna Laurell, Anders Kjellman, Bohuslav Melichar, Pablo Maroto Rey, Henryk Zieliński, Felipe Villacampa, Pierre Bigot, Bajory Zoltan, Omi Parikh, David Vazquez Alba, Åsa Jellvert, Tibor Flaskó, Enrique Gallardo, Maria José Ribal Caparrós, Gunta Purkalne, Peter Suenaert, Alex Karlsson-Parra, Börje Ljungberg

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

    Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms oleh Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

    Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms oleh Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: